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There is a growing public health need for effective preventive interventions against dengue disease. Not only
are the number of cases increasing as the disease spreads to new areas, but explosive outbreaks are occurring.
It is estimated that more than 40% of world population is at risk of dengue infection. Dengue disease is the
most common mosquito-borne disease, transmitted by the bite of the female Aedes aegypty mosquito and
caused by four distinct but closely related viruses, termed serotypes 1-4 (DENV1-4). The infection can be
asymptomatic or a self-limited, acute febrile disease ranging in severity. Recovery from one serotype gives
lifelong immunity to that particular strain, though a second infection by a different serotype can lead to dengue
haemorrhagic fever (DHF), which has 2.5% mortality rate (Figure 1).
Additionally Dengue effects disproportionately LMICs, where the probative costs have slowed the development
and distribution of prophylactics. Currently control measures rely on targeting mosquito vectors. However, the
effectiveness of the applied techniques is often questionable 1,2. Equally, up to now, there is only one licensed
dengue vaccine, Dengvaxia® (CYD-TDV), which has been shown to have some limitations, namely the lower
efficacy against serotype 2 as well as lower protective efficacy in children under 9 years old and dengue-naïve
individuals, in whom it increases the risk of hospitalization and severe dengue 3. Therefore, a safe, effective and
affordable dengue vaccine against the four strains would represent a major therapeutic outcome for the control
of the disease and could be an important tool for reducing dengue morbidity and mortality 2. For this reason, the
development of alternative cost-effective platform for the delivery of a multicompetent Dengue vaccine would
constitute a major therapeutic outcome.
The focus of this study, carried out in collaboration with PT Bio Farma, Indonesia, is to create a platform for
dengue production, which can be afforded and used by LMICs. The platform being developed uses yeast Pichia
pastoris, a versatile and potentially cost-effective factory for the production of Virus-Like-Particles (VLP) for four
dengue virus serotypes as a vaccine candidate. We are investigating the upstream design space to optimize
both quantity and quality of the dengue vaccine prototypes (DENV1-4 vaccine). We will focus our presentation
on reporting the optimisation of the upstream processing design space for the production of the serotypes, also
we will report on both the quantity and the quality of the desired product, before purification steps.
Furthermore, we will share our experience on how international industrial-academic partnership can successfully
develop tools and technologies to de-risk scale-up and enable rapid response.

Figure 1: Dengue disease progression
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